Achieve Life Sciences Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, executive compensation, and an amendment to increase authorized shares. A quorum was present, voting was completed, and results will be disclosed in a forthcoming Form 8-K.
-
Strong capital raise and new leadership position the company for NDA resubmission in Q4 2026 and a first-half 2027 commercial launch, with U.S.-based manufacturing and robust clinical data supporting cytisinicline’s potential as a first-in-class therapy for smoking and vaping cessation.
Fiscal Year 2025
-
NDA for cytisinicline accepted, with commercial launch targeted for 1H 2027 and strong clinical, regulatory, and commercial progress in 2025. U.S. manufacturing established to secure supply, and payer engagement is underway to support access at launch.
-
Major regulatory milestones achieved with FDA acceptance of the NDA for cytisinicline and receipt of a priority voucher for vaping, expediting review and potential launch. Strong cash position supports operations into late 2026, with additional funding needed for the vaping study.
-
FDA accepted the NDA for cytisinicline, a potential first-in-class nicotine dependence therapy in two decades, with robust clinical data and a late 2026 launch targeted. Commercialization leverages Omnicom for agile outreach, and a $49M raise secures funding through key milestones.
-
Three major milestones achieved: NDA submission for cytisinicline, Omnicom partnership for commercial launch, and a $49M capital raise. Q2 ended with $55.4M in cash, supporting operations into H2 2026, with product approval and launch targeted for late 2026.
-
Cytisinicline is advancing as a novel treatment for nicotine dependence, with NDA filing imminent and FDA approval targeted for mid-2026. Robust clinical data show superior efficacy and safety versus current options, and a digital-first launch strategy aims to capture a large, underserved market.
-
NDA submission for cytisinicline is on track for June, supported by strong Phase III results and long-term safety data. Financial discipline remains a priority, with $23.2 million in cash and a net loss of $12.8 million for Q1 2025. Commercial launch is targeted for 2026.
-
Cytisinicline is nearing NDA submission for smoking cessation, with a U.S. launch targeted for late 2026 and vaping cessation by 2027–2028. Clinical trials show superior efficacy and tolerability versus existing treatments, and a focused, data-driven launch strategy will target high-prescribing physicians and motivated quitters.
-
Cytisinicline, a redesigned smoking cessation drug, demonstrated strong efficacy and safety in phase 3 trials and is set for FDA NDA submission next quarter. A digital-first commercial strategy targets key prescribers and patients, with global partnerships and new indications, including vaping, in development.
Fiscal Year 2024
-
NDA submission for cytisinicline as a new smoking cessation therapy is on track for next quarter, with commercial launch planned for Q3 2026. Cash runway extends into Q3 2025, and commercial readiness is advancing, targeting high-volume prescribers and motivated quitters.
-
Management strengthened for commercialization as cytisinicline advances toward NDA submission in Q2 2025, with FDA Breakthrough Therapy designation for vaping cessation and a $20M SVB refinancing. Cash runway extends into H2 2025; Q3 net loss rose due to trial costs.
-
Cytisinicline development advanced with FDA Breakthrough Therapy designation for vaping cessation and rapid ORCA-OL trial enrollment. Cash runway extends into H2 2025 after $20M debt refinancing, with NDA submission for smoking cessation on track for H1 2025.